Diagnostic accuracy of extended biopsies for the staging of microfocal prostate cancers in autopsy specimen

Nicolas B. Delongchamps, G. de la Roza, V. Chandan, R. Jones, G. Threatte, M. Jumbelic, G. P. Haas

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Clinically insignificant prostate cancers may be predicted when biopsies show a microfocal cancer (MiFC). However, at least one-third of MiFC are underestimated by biopsies. The aim of this study was to evaluate the staging accuracy of different biopsy regimen showing a MiFC. We performed 18 biopsy cores on 164 autopsy prostates. Six cores were taken from the mid-peripheral zone (MPZ), 6 from the lateral PZ (LPZ) and 6 from the central zone (CZ). We tested seven different biopsy regimens by distinguishing the MPZ, LPZ or CZ biopsies either separately or associated with each other. Of the cancers detected by biopsies, we selected those showing a MiFC and compared our findings with whole mount analysis. The positive predictive value of a MiFC referred to how often, when needle biopsies showed a MiFC, there was a clinically insignificant cancer on whole mount prostate analysis. We found that the positive predictive value of a MiFC on 6 or 12 biopsy cores was similar irrespective of biopsy location (P ≈ 1). On MPZ, MPZ plus LPZ and all 18 biopsies, it was 40, 70 and 87%, respectively (P<0.1). Tumor volume of cancers showing a MiFC on MPZ biopsies was significantly higher than those showing a MiFC on MPZ plus LPZ, or all 18 biopsies (P<0.05). These results show that performing additional cores in case of MiFC on sextant biopsies may help differentiating significant from insignificant cancers.

Original languageEnglish (US)
Pages (from-to)137-142
Number of pages6
JournalProstate Cancer and Prostatic Diseases
Volume12
Issue number2
DOIs
StatePublished - 2009
Externally publishedYes

Fingerprint

Autopsy
Prostatic Neoplasms
Biopsy
Neoplasms
Prostate
Needle Biopsy
Tumor Burden

ASJC Scopus subject areas

  • Oncology
  • Urology
  • Cancer Research

Cite this

Delongchamps, N. B., de la Roza, G., Chandan, V., Jones, R., Threatte, G., Jumbelic, M., & Haas, G. P. (2009). Diagnostic accuracy of extended biopsies for the staging of microfocal prostate cancers in autopsy specimen. Prostate Cancer and Prostatic Diseases, 12(2), 137-142. https://doi.org/10.1038/pcan.2008.38

Diagnostic accuracy of extended biopsies for the staging of microfocal prostate cancers in autopsy specimen. / Delongchamps, Nicolas B.; de la Roza, G.; Chandan, V.; Jones, R.; Threatte, G.; Jumbelic, M.; Haas, G. P.

In: Prostate Cancer and Prostatic Diseases, Vol. 12, No. 2, 2009, p. 137-142.

Research output: Contribution to journalArticle

Delongchamps, NB, de la Roza, G, Chandan, V, Jones, R, Threatte, G, Jumbelic, M & Haas, GP 2009, 'Diagnostic accuracy of extended biopsies for the staging of microfocal prostate cancers in autopsy specimen', Prostate Cancer and Prostatic Diseases, vol. 12, no. 2, pp. 137-142. https://doi.org/10.1038/pcan.2008.38
Delongchamps, Nicolas B. ; de la Roza, G. ; Chandan, V. ; Jones, R. ; Threatte, G. ; Jumbelic, M. ; Haas, G. P. / Diagnostic accuracy of extended biopsies for the staging of microfocal prostate cancers in autopsy specimen. In: Prostate Cancer and Prostatic Diseases. 2009 ; Vol. 12, No. 2. pp. 137-142.
@article{5445847fd3754eecb748648ce1d771ec,
title = "Diagnostic accuracy of extended biopsies for the staging of microfocal prostate cancers in autopsy specimen",
abstract = "Clinically insignificant prostate cancers may be predicted when biopsies show a microfocal cancer (MiFC). However, at least one-third of MiFC are underestimated by biopsies. The aim of this study was to evaluate the staging accuracy of different biopsy regimen showing a MiFC. We performed 18 biopsy cores on 164 autopsy prostates. Six cores were taken from the mid-peripheral zone (MPZ), 6 from the lateral PZ (LPZ) and 6 from the central zone (CZ). We tested seven different biopsy regimens by distinguishing the MPZ, LPZ or CZ biopsies either separately or associated with each other. Of the cancers detected by biopsies, we selected those showing a MiFC and compared our findings with whole mount analysis. The positive predictive value of a MiFC referred to how often, when needle biopsies showed a MiFC, there was a clinically insignificant cancer on whole mount prostate analysis. We found that the positive predictive value of a MiFC on 6 or 12 biopsy cores was similar irrespective of biopsy location (P ≈ 1). On MPZ, MPZ plus LPZ and all 18 biopsies, it was 40, 70 and 87{\%}, respectively (P<0.1). Tumor volume of cancers showing a MiFC on MPZ biopsies was significantly higher than those showing a MiFC on MPZ plus LPZ, or all 18 biopsies (P<0.05). These results show that performing additional cores in case of MiFC on sextant biopsies may help differentiating significant from insignificant cancers.",
author = "Delongchamps, {Nicolas B.} and {de la Roza}, G. and V. Chandan and R. Jones and G. Threatte and M. Jumbelic and Haas, {G. P.}",
year = "2009",
doi = "10.1038/pcan.2008.38",
language = "English (US)",
volume = "12",
pages = "137--142",
journal = "Prostate Cancer and Prostatic Diseases",
issn = "1365-7852",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Diagnostic accuracy of extended biopsies for the staging of microfocal prostate cancers in autopsy specimen

AU - Delongchamps, Nicolas B.

AU - de la Roza, G.

AU - Chandan, V.

AU - Jones, R.

AU - Threatte, G.

AU - Jumbelic, M.

AU - Haas, G. P.

PY - 2009

Y1 - 2009

N2 - Clinically insignificant prostate cancers may be predicted when biopsies show a microfocal cancer (MiFC). However, at least one-third of MiFC are underestimated by biopsies. The aim of this study was to evaluate the staging accuracy of different biopsy regimen showing a MiFC. We performed 18 biopsy cores on 164 autopsy prostates. Six cores were taken from the mid-peripheral zone (MPZ), 6 from the lateral PZ (LPZ) and 6 from the central zone (CZ). We tested seven different biopsy regimens by distinguishing the MPZ, LPZ or CZ biopsies either separately or associated with each other. Of the cancers detected by biopsies, we selected those showing a MiFC and compared our findings with whole mount analysis. The positive predictive value of a MiFC referred to how often, when needle biopsies showed a MiFC, there was a clinically insignificant cancer on whole mount prostate analysis. We found that the positive predictive value of a MiFC on 6 or 12 biopsy cores was similar irrespective of biopsy location (P ≈ 1). On MPZ, MPZ plus LPZ and all 18 biopsies, it was 40, 70 and 87%, respectively (P<0.1). Tumor volume of cancers showing a MiFC on MPZ biopsies was significantly higher than those showing a MiFC on MPZ plus LPZ, or all 18 biopsies (P<0.05). These results show that performing additional cores in case of MiFC on sextant biopsies may help differentiating significant from insignificant cancers.

AB - Clinically insignificant prostate cancers may be predicted when biopsies show a microfocal cancer (MiFC). However, at least one-third of MiFC are underestimated by biopsies. The aim of this study was to evaluate the staging accuracy of different biopsy regimen showing a MiFC. We performed 18 biopsy cores on 164 autopsy prostates. Six cores were taken from the mid-peripheral zone (MPZ), 6 from the lateral PZ (LPZ) and 6 from the central zone (CZ). We tested seven different biopsy regimens by distinguishing the MPZ, LPZ or CZ biopsies either separately or associated with each other. Of the cancers detected by biopsies, we selected those showing a MiFC and compared our findings with whole mount analysis. The positive predictive value of a MiFC referred to how often, when needle biopsies showed a MiFC, there was a clinically insignificant cancer on whole mount prostate analysis. We found that the positive predictive value of a MiFC on 6 or 12 biopsy cores was similar irrespective of biopsy location (P ≈ 1). On MPZ, MPZ plus LPZ and all 18 biopsies, it was 40, 70 and 87%, respectively (P<0.1). Tumor volume of cancers showing a MiFC on MPZ biopsies was significantly higher than those showing a MiFC on MPZ plus LPZ, or all 18 biopsies (P<0.05). These results show that performing additional cores in case of MiFC on sextant biopsies may help differentiating significant from insignificant cancers.

UR - http://www.scopus.com/inward/record.url?scp=67349173195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349173195&partnerID=8YFLogxK

U2 - 10.1038/pcan.2008.38

DO - 10.1038/pcan.2008.38

M3 - Article

C2 - 18626509

AN - SCOPUS:67349173195

VL - 12

SP - 137

EP - 142

JO - Prostate Cancer and Prostatic Diseases

JF - Prostate Cancer and Prostatic Diseases

SN - 1365-7852

IS - 2

ER -